Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

hypoglycaemia

- PMLiVE

The digital transformation of market research

How technology is bringing new clarity to the patient voice

- PMLiVE

Digital disruption

The pressure to transform will come from all stakeholders, not just technologists

- PMLiVE

Novo Nordisk: Tresiba makes a solid start

Long-acting insulin capturing share of diabetes market

- PMLiVE

The rules of digital patient engagement

More needs to be done to recruit patients to clinical trials

- PMLiVE

Integrating multichannel marketing

External forces are driving the need for pharma to use a greater variety of channels to reach customers

- PMLiVE

GSK gets OK in US for diabetes drug albiglutide

Once-weekly Tanzeum will compete against Victoza and Byetta after FDA approval

- PMLiVE

Lilly to use real-world data in diabetes collaboration

Partners with T1D Exchange to research ways to provide type 1 diabetes care

- PMLiVE

Back to mobile basics

Texting as part of a wider healthcare plan

- PMLiVE

Novo Nordisk chooses Mexico to launch urban diabetes plan

‘Cities Changing Diabetes’ partnership programme launches in Mexico City before global roll out

- PMLiVE

MannKind’s inhaled insulin backed for US approval

Afrezza finally on course for FDA approval in diabetes after two rejections

- PMLiVE

EMA clears GSK’s diabetes therapy Eperzan

Once-weekly GLP-1 therapy will line-up against Victoza and Byetta

- PMLiVE

Life sciences sector ‘aggressively embracing’ new technology

Technology-driven approaches drive breakthroughs, says a new study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links